Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk-Reference-Cited by-同舟云学术

Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk

Published:2020-07-07 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

König Laila,Haering Peter,Lang Clemens,Splinter Mona,von Nettelbladt Bastian,Weykamp Fabian,Hoegen Philipp,Lischalk Jonathan W.,Herfarth Klaus,Debus Jürgen,Hörner-Rieber Juliane

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference43 articles.

1. The use of risk estimation models for the induction of secondary cancers following radiotherapy;Dasu;Acta Oncol.,2005

2. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial;Engert;Lancet.,2012

3. Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation;Schneider;Radiat Res.,2000

4. Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose;Schneider;Int J Radiat Oncol Biol Phys.,2005

5. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?;Girinsky;Int J Radi Oncol Biol Phys.,2006

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary cancer risk in six anatomical sites when using PAT, IMPT, and VMAT/IMRT radiotherapy;Radiotherapy and Oncology;2024-10

2. Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before;Hematological Oncology;2024-04-23

3. The clinical roadmap in a dual-beam hadrontherapy centre: tumour-based and patient-tailored selection criteria, management of range uncertainties and oncological patient pathway;Health and Technology;2024-04-19

4. Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy;Current Treatment Options in Oncology;2023-09-20

5. Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration;Advances in Radiation Oncology;2023-01